How Will Clinicians and Pharmacy Directors Respond to the Increasing Number of Treatment Options for Hepatitis C Virus? - On Demand

Based on our Physician & Payer Forum report entitled Hepatitis C: Reimbursement and Uptake of Novel Antivirals Among Payers and Prescribers, Decision Resources is offering an exclusive webinar entitled How Will Clinicians and Pharmacy Directors Respond to the Increasing Number of Treatment Options for Hepatitis C Virus? Because this webinar features major report findings, it is ONLY available to purchasers of this report.

Recorded live on Wednesday, July 28, 2010

This webinar, presented by Decision Resources Analyst Alexandra Makarova, M.D., Ph.D., answers the following questions:  

• To what extent and for what reasons are physicians delaying HCV treatment in newly diagnosed patients and what proportion of patients are delaying therapy until the launch of novel HCV therapies? What attributes of emerging HCV therapies have the most power to persuade clinicians to prescribe a new treatment in place of current therapies? What factors will have the greatest impact on pharmacy directors’ formulary assessment of novel agents?
• How will physicians use telaprevir and boceprevir and will physicians delay treatment with these two agents in anticipation of follow-on HCV-specific antivirals? What is the relationship between the price point of novel antivirals and tier placement and what usage restrictions will exist?
• What improvements do clinicians expect from follow-on HCV-specific antiviral agents and what improvements do pharmacy directors expect from these agents in order to add them to their formularies?
• Will physicians use novel triple-therapy regimens in patients who fail treatment with other triple-therapy regimens and, if so, what data will convince clinicians to do so? How willing are clinicians to combine novel anti-HCV agents with each other and with peg-IFN/ribavirin to form triple and quadruple therapy regimens? What data will physicians require before incorporating quadruple therapy regimens into their treatment practices? How willing are pharmacy directors to reimburse multiple lines of therapy and four-drug combinations?
• What is physician opinion about potential fixed-dose combinations of HCV-specific antivirals and acceptable efficacy of all-oral HCV treatment regimens? Will pharmacy directors reimburse fixed-dose oral combinations of HCV therapies?

Contact us to learn how you can purchase this Physician & Payer Forum report and access a recorded playback of this event.

Click here to view the invite.